CVspectrum.org
GO TO: Register Now! SIGN IN



SEARCH


Advanced Search >>
BROWSE





Metabolic Syndrome

News

Featured Slide

No news available

Editorial

  • Implications of ASCOT and CARDS
    Christie M. Ballantyne, MD
    Clinical trial evidence has established the benefit of lipid-regulating statin therapy in patients with elevated low-density lipoprotein cholesterol (LDL-C), but in a growing number of patients, cardiovascular risk is increased by the presence of the metabolic syndrome, characterized by elevated triglycerides, low high-density lipoprotein cholesterol (HDL-C), hypertension, and insulin resistance.

Continuing Education

CVspectrum.org

The FCG Institute for Continuing Education Technology partner: ISIS1
Emeritus Educational SciencesImprint Science
Acumentis
© Copyright 2009 CVspectrum.org.      About CVspectrum | Terms of Use | Privacy Policy | Site Map | Contact Us Supported by educational grants from Abbott Laboratories, AstraZeneca Pharmaceuticals LP and Takeda Pharmaceuticals North America, Inc.